Key result
Paeoniflorin (300 mg/kg daily) significantly inhibited chronic hypoxia/SU5416-induced elevations of right ventricular systolic pressure and right ventricular hypertrophy in rats.
Why the study?
Endothelial cell dysfunction is a hallmark of pulmonary arterial hypertension, and although paeoniflorin has endothelial-protective and other beneficial properties, its effects on PAH remained unknown.
Does Paeoniflorin ameliorate chronic hypoxia/SU5416-induced pulmonary arterial hypertension in rats?
Does Paeoniflorin ameliorate chronic hypoxia/SU5416-induced pulmonary arterial hypertension in rats?
Paeoniflorin ameliorates pulmonary arterial hypertension in a rat model by inhibiting BMPR2 down-regulation-mediated endothelial-to-mesenchymal transition.
BACKGROUND: Endothelial cells dysfunction is one of the hallmark pathogenic features of pulmonary arterial hypertension (PAH). Paeoniflorin (PF) is a monoterpene glycoside with endothelial protection, vasodilation, antifibrotic, anti-inflammatory and antioxidative properties. However, the effects of PF on PAH remain unknown. METHODS: with or without PF treatment. RESULTS: Hemodynamics analysis showed that prophylactic treatment with PF (300 mg/kg i.g. daily for 21 days) significantly inhibited chronic hypoxia/SU5416-induced elevations of right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index in rats. Meanwhile, PF significantly reduced pulmonary vascular remodeling, as well as alleviated collagen deposition in lungs and right ventricles in SuHx rats. Additionally, PF inhibited SuHx-induced down-regulation of endothelial marker (vascular endothelial cadherin) and up-regulation of mesenchymal markers (fibronectin and vimentin) in lung, suggesting that PF could inhibit SuHx-induced endothelial-to-mesenchymal transition (EndMT) in lung. Further in vitro studies confirmed that PF treatment suppressed hypoxia-induced EndMT in HPAECs, which was abolished by the knockdown of bone morphogenetic protein receptor type 2 (BMPR2) in HPAECs. CONCLUSION: Taken together, our findings suggest that PF ameliorates BMPR2 down-regulation-mediated EndMT and thereafter alleviates SuHx-induced PAH in rats.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2020) studied Pulmonary arterial hypertension. Paeoniflorin vs. without PF treatment was evaluated on right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index. Paeoniflorin (300 mg/kg daily) significantly inhibited chronic hypoxia/SU5416-induced elevations of right ventricular systolic pressure and right ventricular hypertrophy in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: